Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant

View ORCID ProfilePaul T. Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona Burns, David R. Chadwick, Rebecca Clark, Catherine Cosgrove, View ORCID ProfileJames Galloway, Anna L. Goodman, Amardeep Heer, Andrew Higham, Shalini Iyengar, Arham Jamal, Christopher Jeanes, Philip A. Kalra, Christina Kyriakidou, Daniel F. McAuley, Agnieszka Meyrick, Angela M. Minassian, Jane Minton, Patrick Moore, Imrozia Munsoor, Helen Nicholls, Orod Osanlou, Jonathan Packham, Carol H. Pretswell, Alberto San Francisco Ramos, Dinesh Saralaya, Ray P. Sheridan, Richard Smith, Roy L. Soiza, Pauline A. Swift, View ORCID ProfileEmma C. Thomson, Jeremy Turner, Marianne Elizabeth Viljoen, Gary Albert, Iksung Cho, Filip Dubovsky, Greg Glenn, Joy Rivers, Andreana Robertson, Kathy Smith, View ORCID ProfileSeth Toback
doi: https://doi.org/10.1101/2021.05.13.21256639
Paul T. Heath
1Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK
FRCPCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul T. Heath
Eva P. Galiza
1Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Neil Baxter
2Stockport NHS Foundation Trust, Stepping Hill Hospital, Poplar Grove, Stockport, UK
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Boffito
3Chelsea and Westminster Hospital NHS Foundation Trust and Imperial College London, London, UK
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan Browne
4Royal Cornwall Hospitals NHS Trust, Truro, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona Burns
5Institute for Global Health, University College London, and Royal Free London NHS Foundation Trust, London, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Chadwick
6Centre for Clinical Infection, South Tees Hospitals NHS Foundation Trust, James Cook University Hospital, Middlesbrough, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Clark
7Layton Medical Centre, Blackpool, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Cosgrove
1Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Galloway
8Centre for Rheumatic Disease, Kings College London, London, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James Galloway
Anna L. Goodman
9Department of Infectious Diseases, Guy’s and St Thomas’ NHS Foundation Trust, and MRC Clinical Trials Unit at University College London, London, UK
DPhil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amardeep Heer
10Lakeside Healthcare Research, Lakeside Surgeries Corby, Northants, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Higham
11University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shalini Iyengar
12Accelerated Enrollment Solutions, Synexus Hexham Dedicated Research Site, Hexham General Hospital, Hexham, UK
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arham Jamal
13Accelerated Enrollment Solutions, Synexus Thames Valley Dedicated Research Site, Wellington House, Worton Drive, Worton Grange, Reading, UK
MBBCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Jeanes
14Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, UK
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip A. Kalra
15Salford Royal NHS Foundation Trust, Northern Care Alliance, Salford, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Kyriakidou
16Accelerated Enrollment Solutions, Synexus Midlands Dedicated Research Site, Birmingham Research Park, Birmingham, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel F. McAuley
17Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University of Belfast and Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnieszka Meyrick
18Accelerated Enrollment Solutions, Synexus Merseyside Dedicated Research Site, Burlington House, Waterloo, Liverpool, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela M. Minassian
19Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
DPhil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Minton
20St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Moore
21The Adam Practice, Poole, Dorset, UK, and University Hospital Southampton NHS Foundation Trust, Southampton, UK
BScBM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Imrozia Munsoor
22Accelerated Enrollment Solutions, Synexus Glasgow Dedicated Research Site, Venture Building, Kelvin Campus, Glasgow, Scotland, UK
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Nicholls
23Accelerated Enrollment Solutions, Synexus Wales Dedicated Research Site, Riverside Court Gwaelod-y-Garth, Cardiff, Wales, UK
MBBCh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orod Osanlou
24School of Medical Sciences, Bangor University, and Betsi Cadwaladr University Health Board, Wales, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Packham
25Division of Epidemiology and Public Health, University of Nottingham, Nottingham UK, and Haywood Hospital, Midlands Partnership NHS Foundation Trust, Stafford, UK
DM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol H. Pretswell
26Accelerated Enrollment Solutions, Synexus Lancashire Dedicated Research Site, Matrix Park Buckshaw Village, Chorley, Lancashire, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto San Francisco Ramos
1Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK
MB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dinesh Saralaya
27National Institute for Health Research Patient Recruitment Centre and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ray P. Sheridan
28Royal Devon & Exeter Hospital, Exeter, Devon, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Smith
29East Suffolk and North Essex NHS Foundation Trust and University of Essex, Wivenhoe Park, Colchester, Essex, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy L. Soiza
30Aberdeen Royal Infirmary, NHS Grampian, and Ageing Clinical and Experimental Research (ACER) Group, University of Aberdeen, Aberdeen, Scotland, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pauline A. Swift
31Renal Services, Epsom and St Helier University Hospitals NHS Trust, London, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma C. Thomson
32MRC-University of Glasgow Centre for Virus Research, and Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, Scotland, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emma C. Thomson
Jeremy Turner
14Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, UK
DPhil (Oxon)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Elizabeth Viljoen
33Accelerated Enrollment Solutions, Synexus Manchester Dedicated Research Site, Kilburn House, Manchester, UK
MBChB
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Albert
34Novavax, Inc., Gaithersburg, MD, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iksung Cho
34Novavax, Inc., Gaithersburg, MD, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Dubovsky
34Novavax, Inc., Gaithersburg, MD, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Glenn
34Novavax, Inc., Gaithersburg, MD, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joy Rivers
34Novavax, Inc., Gaithersburg, MD, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreana Robertson
34Novavax, Inc., Gaithersburg, MD, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathy Smith
34Novavax, Inc., Gaithersburg, MD, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seth Toback
34Novavax, Inc., Gaithersburg, MD, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Seth Toback
  • For correspondence: stoback{at}novavax.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Covid-19 vaccines are urgently needed, especially against emerging variants. NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 rS) nanoparticle vaccine containing trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant.

Methods A phase 3, randomized, observer-blinded, placebo-controlled trial was conducted in adults 18-84 years old who received two intramuscular 5-µg doses, 21 days apart, of NVX-CoV2373 or placebo (1:1) across 33 sites in the United Kingdom. The primary efficacy endpoint was virologically confirmed symptomatic Covid-19 with onset 7 days after second vaccination in serologically negative participants.

Results A total of 15,187 participants were randomized, of whom 7569 received NVX-CoV2373 and 7570 received placebo; 27.2% were 65 years or older, 44.7% had comorbidities and 4.2% had baseline serological evidence of SARS-CoV-2. There were 10 cases of Covid-19 among NVX-CoV2373 recipients and 96 cases among placebo recipients, with symptom onset at least 7 days after second vaccination; NVX-CoV2373 was 89.7% (95% confidence interval, 80.2 to 94.6) effective in preventing Covid-19, with no hospitalizations or deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of 96.4% (73.8 to 99.5) and 86.3% (71.3 to 93.5) against the prototype strain and B.1.1.7 variant, respectively. Vaccine efficacy was similar across subgroups, including participants with comorbidities and those ≥65 years old. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups.

Conclusion A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.1.7 variant, and had a reassuring safety profile.

(Funded by Novavax, Inc. EudraCT number, 2020-004123-16).

Competing Interest Statement

Disclosure forms provided by the authors will be available with the full text of this article upon publication.

Clinical Trial

NCT04583995

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04583995

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB

Funding Statement

Funded by Novavax, Inc. EudraCT number, 2020-004123-16

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol was approved by the North West-Greater Manchester Central Research Ethics Committee (Ref 20/NW/03/99) and was performed in accordance with the International Council for Harmonisation Good Clinical Practice guidelines (see protocol in the Supplementary Appendix).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Limited data will be available on the following websites:

https://clinicaltrials.gov/ct2/show/NCT04583995

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
Paul T. Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona Burns, David R. Chadwick, Rebecca Clark, Catherine Cosgrove, James Galloway, Anna L. Goodman, Amardeep Heer, Andrew Higham, Shalini Iyengar, Arham Jamal, Christopher Jeanes, Philip A. Kalra, Christina Kyriakidou, Daniel F. McAuley, Agnieszka Meyrick, Angela M. Minassian, Jane Minton, Patrick Moore, Imrozia Munsoor, Helen Nicholls, Orod Osanlou, Jonathan Packham, Carol H. Pretswell, Alberto San Francisco Ramos, Dinesh Saralaya, Ray P. Sheridan, Richard Smith, Roy L. Soiza, Pauline A. Swift, Emma C. Thomson, Jeremy Turner, Marianne Elizabeth Viljoen, Gary Albert, Iksung Cho, Filip Dubovsky, Greg Glenn, Joy Rivers, Andreana Robertson, Kathy Smith, Seth Toback
medRxiv 2021.05.13.21256639; doi: https://doi.org/10.1101/2021.05.13.21256639
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
Paul T. Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona Burns, David R. Chadwick, Rebecca Clark, Catherine Cosgrove, James Galloway, Anna L. Goodman, Amardeep Heer, Andrew Higham, Shalini Iyengar, Arham Jamal, Christopher Jeanes, Philip A. Kalra, Christina Kyriakidou, Daniel F. McAuley, Agnieszka Meyrick, Angela M. Minassian, Jane Minton, Patrick Moore, Imrozia Munsoor, Helen Nicholls, Orod Osanlou, Jonathan Packham, Carol H. Pretswell, Alberto San Francisco Ramos, Dinesh Saralaya, Ray P. Sheridan, Richard Smith, Roy L. Soiza, Pauline A. Swift, Emma C. Thomson, Jeremy Turner, Marianne Elizabeth Viljoen, Gary Albert, Iksung Cho, Filip Dubovsky, Greg Glenn, Joy Rivers, Andreana Robertson, Kathy Smith, Seth Toback
medRxiv 2021.05.13.21256639; doi: https://doi.org/10.1101/2021.05.13.21256639

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3298)
  • Dentistry and Oral Medicine (365)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1173)
  • Epidemiology (13384)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5157)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3274)
  • Health Policy (1143)
  • Health Systems and Quality Improvement (1193)
  • Hematology (432)
  • HIV/AIDS (1019)
  • Infectious Diseases (except HIV/AIDS) (14636)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (478)
  • Medical Ethics (127)
  • Nephrology (525)
  • Neurology (4930)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (727)
  • Orthopedics (282)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (544)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4218)
  • Public and Global Health (7512)
  • Radiology and Imaging (1708)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (549)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)